Clinical Research Directory
Browse clinical research sites, groups, and studies.
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Sponsor: LTZ Therapeutics, Inc.
Summary
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Official title: A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2026-01-29
Completion Date
2028-02
Last Updated
2026-02-10
Healthy Volunteers
No
Conditions
Interventions
LTZ-301
LTZ-301 will be dosed IV, in initial 28 day cycles. First cycle dosing is every week. Second through fifth cycles are dosed every 2 weeks. Sixth cycle and beyond are 21 day cycles, and are dosed once every 3 weeks.
LTZ-301
LTZ-301will be dosed IV, as above
LTZ-301
LTZ-301will be dosed IV, as above
Locations (5)
City of Hope
Duarte, California, United States
Washington University School of Medicine
St Louis, Missouri, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Tennessee Oncology
Nashville, Tennessee, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States